Lumos, Tali Resources, Osteopore, ClearVue & Evion

Lumos Diagnostics (ASX: LDX)

176 % (8.5C – 21C)

Bulls N ‘Bears’ Week runners Lumos Diagnostics, Faz Scientific International, announced that it has signed a very important, exclusive US distribution and procurement agreement worth 317 million US dollars ($ 487 million) ($ 487 million).

Lumos is the leader in Fast Maintenance Point (POC) diagnostic technologies, and specializes in the development and commercialization of tests to help doctors to correctly identify and manage infectious diseases.

The flagship product Febridx is a rapid test that differentiates from bacterial viral respiratory infections in just 10 minutes using a finger stick blood sample. More importantly, technology can help to address antibiotic excessive use by providing clear clinical guidance for prescriptions.

The US, the mainland China and Hong Kong operations, phase, registered technologies using new diagnostic tools and services for cancer and infectious diseases provides a multic-mileyar dollar player.

The agreement has been for the exclusive distribution of Pebridx in the Juicy US market for six years – Lumos’s share price saw Skyroket from 176 percent to the highest level on Wednesday.

The agreement includes an additional payment of US $ 7.5 million in the unmissable exclusivity payment for the signature and unmissable prepaid purchasing orders to be paid in three slices.

Bookmakers bet on Lumos’s potential to transform respiratory diagnoses in the world’s largest health market. This agreement is not only the dollar and the cents, but Lumos aligns Lumos with the proven brand record of the Phase Scientific of the Phase Scientific and more than 100 million test sales.

With an increasing global concern with antibiotic resistance, Lumos’s technology can save health systems billions and improve patient consequences. This week’s share price increase may be a appetizer for what will happen if the US Food and Pharmaceutical Administration gives a green light.

Tali Resources Ltd (ASX: TR2)

125 % (20C – 45C)

To finish a second second, even late, asx, who has seen the largest daily list performance over the years, the new Tali Resources. Following the names behind the Western Arunta Darling, the company’s share price rose by 120 percent on Friday, and 100-Bager WA1 sources moved, while the iron was 7.5 million dollars to chase the giant copper deposits of the red-hot West Arunta area.

The Western Arunta region near the Battle of the Western Australia-North region is the latest geological boundary of Australia. Tali, who returned from Agrim’s Limited and directed by WA1 Resources Director Rhys Bradley, said that he rented a gigantic rent of 4000 square kilometers in the greedy region. Rentals are adjacent to Wa1’s discovery of Luni Niobium-Rades Earths.

Tali’s mission is a strategic discovery to define large -scale mineral deposits and reproduce its previous success with copper as the primary target.

The gardens clearly see the potential to repeat WA1’s success with Tali’s wide -rental package and focus on copper, a metal that demands a red warm demand for global clean energy transition. On the first day of trade, the nutritional craze was traded from an increase of 20 ° C per share of more than $ 1 million to 45 ° C.

The 7.5 million dollar war polls, Tali’s firepower to initiate aggressive discovery, and drilling plans were set to test high priority targets during the spread period.

The price price made a warm start, already doubled on the first day, but Tali still has a long way to live Wa1’s Dream 2022 public offering.

Osteopore Ltd (ASX: OSX)

100 % increase (1C – 2C)

The regenerative medicine company Osteopore, which was tanned in the list of the week’s runners this week, was limited. The company withdrew from the doors after locking the profitable market approval for 3D printed implants in Switzerland within the scope of the European Union’s medical device arrangements.

Osteopore’s patent -protected piers are made using a registered production technique with a naturally dissolved polymer over time, as they are replaced with a healthy, new growth bone texture.

Biologically arranged implants stimulate natural bone healing and can be used in neurosurgery, orthopedics and craniophacial applications to significantly reduce the commonly associated postoperative complications with permanent bone implants.

Osteopore, which operates globally, including Europe, Asia and the United States, is partnership with giants such as Zimmer Biomet to distribute innovative implants.

The company’s share price doubled on Monday and closed as 2C per share with a stock of 1 million dollars of 1C last week.

The company says that the high -valuable implant series, market leader Zimmer Biomet, offers the opportunity to offer high -valuable implants to Swiss and larger European markets.

This week’s milestone is ready for Osteopore’s 2023 transition and the 2024 exclusive distribution agreement with Zimmer Biomet, and completing special implants aiming at the US $ 527.6 million Cranial implant market. The market is expected to reach 26.7 billion dollars for special implants until 2029.

Investors saw Osteopore’s Switzerland’s opening as a gateway for a wider European adoption, especially in the high -valuable markets of Zimmer Biomet.

Osteopore’s technology is simple but bright in a world where traditional implants need to face a technology. Europe’s private implant market is looking at explosive growth, this week’s share price increase reflects that they may be leading for struggling biotechnology.

Clearvue Technologies Ltd (ASX: OSX)

93 % (14C – 27C)

Green-Tech Company is to wear our last runners and fly this week Clearvue technologiesThis says that it is ready to offer a glazed building into a sun photovoltaic series that promises to offer all the groundbreaking Sun Front products.

The company has recently undergone a management renewal and announced on Wednesday that the full certified vacuum integrated solar glass products range, including the coated and spandrels, is ready to be deployed in the projects and immediately.

While the innovative company decreases energy use and maintains glass transparency for aesthetic building design, it develops sun windows that produce electricity and plays in the integrated photovoltaic (BIPV) sector with the building.

Developed by Landglass Technology’s Landvac, vacuum -insulated glass (VIG) units aim at sustainable construction and net zero buildings by integrating solar technology into windows and facades.

First of all, Clearvue’s solutions, which focus on Asian markets such as Hong Kong in Australia, meet the solid fire safety standards for high -rise and high -risk environments.

The company returns to the head this week and saw the star results from the attempt of the VIG units in the center of Hong Kong’s Electrical and Mechanical Services Department.

The trial showed a 4.6-year refund period (2.6 years with subsidies) and 74-125 percent of the energy needs of a 40-storey building.

With the Certificates and a new Hong Kong subsidiary plus Landvac, investors have bets Clearvue’s ability to benefit from Asia’s sustainable building explosion.

The company says that its technology is an excellent harmony for the city centers that compete for net zero carbon targets in Asia, especially in Asia, where high -storey construction explodes.

When Hong Kong is combined with the trial success of the trial, a value of 0.58, the-Standart Windows-Clearvue is well positioned as a leader in energy-saving building design.

With the approval of the Hong Kong government and more Rar -GE plans, the company is preparing to transform skyscrapers into power plants and makes this week’s share price into a clue that the green revolution can be released globally by the Green Revolution.

Does your company on the ASX list do something interesting? Contact: Mattbirney@bullsnbears.com.au